Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy
Abstract Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to recruit T cells toward antigens on the tumor cell surface and, moreover, to activate accessory cells through their immunoglobulin Fc region interacting with activating Fcγ receptors. This scen...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2013-03-01
|
| Series: | Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.2119/molmed.2012.00140 |
| _version_ | 1827875431780450304 |
|---|---|
| author | Nina Eissler Josef Mysliwietz Nina Deppisch Peter Ruf Horst Lindhofer Ralph Mocikat |
| author_facet | Nina Eissler Josef Mysliwietz Nina Deppisch Peter Ruf Horst Lindhofer Ralph Mocikat |
| author_sort | Nina Eissler |
| collection | DOAJ |
| description | Abstract Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to recruit T cells toward antigens on the tumor cell surface and, moreover, to activate accessory cells through their immunoglobulin Fc region interacting with activating Fcγ receptors. This scenario gives rise to additional costimulatory signals required for T cell-mediated tumor cell destruction and induction of an immunologic memory. Here we show in an in vitro system that most effective trAb-dependent T-cell activation and tumor cell elimination are achieved in the presence of dendritic cells (DCs). On the basis of these findings, we devise a novel approach of cancer immunotherapy that combines the specific advantages of trAbs with those of DC-based vaccination. Simultaneous delivery of trAbs and in vitro differentiated DCs resulted in a markedly improved tumor rejection in a murine melanoma model compared with monotherapy. |
| first_indexed | 2024-03-12T17:07:50Z |
| format | Article |
| id | doaj.art-08ec4f4b1668430db55894883c0eab70 |
| institution | Directory Open Access Journal |
| issn | 1076-1551 1528-3658 |
| language | English |
| last_indexed | 2024-03-12T17:07:50Z |
| publishDate | 2013-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Medicine |
| spelling | doaj.art-08ec4f4b1668430db55894883c0eab702023-08-06T11:17:45ZengBMCMolecular Medicine1076-15511528-36582013-03-01191546110.2119/molmed.2012.00140Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor ImmunotherapyNina Eissler0Josef Mysliwietz1Nina Deppisch2Peter Ruf3Horst Lindhofer4Ralph Mocikat5Institut für Molekulare Immunologie, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und UmweltInstitut für Molekulare Immunologie, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und UmweltInstitut für Molekulare Immunologie, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und UmweltTrion ResearchTrion ResearchInstitut für Molekulare Immunologie, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und UmweltAbstract Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to recruit T cells toward antigens on the tumor cell surface and, moreover, to activate accessory cells through their immunoglobulin Fc region interacting with activating Fcγ receptors. This scenario gives rise to additional costimulatory signals required for T cell-mediated tumor cell destruction and induction of an immunologic memory. Here we show in an in vitro system that most effective trAb-dependent T-cell activation and tumor cell elimination are achieved in the presence of dendritic cells (DCs). On the basis of these findings, we devise a novel approach of cancer immunotherapy that combines the specific advantages of trAbs with those of DC-based vaccination. Simultaneous delivery of trAbs and in vitro differentiated DCs resulted in a markedly improved tumor rejection in a murine melanoma model compared with monotherapy.https://doi.org/10.2119/molmed.2012.00140Trifunctional Bispecific AntibodyFACS StainingInduce Tumor Cell KillingCatumaxomabKill Tumor Cells |
| spellingShingle | Nina Eissler Josef Mysliwietz Nina Deppisch Peter Ruf Horst Lindhofer Ralph Mocikat Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy Molecular Medicine Trifunctional Bispecific Antibody FACS Staining Induce Tumor Cell Killing Catumaxomab Kill Tumor Cells |
| title | Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy |
| title_full | Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy |
| title_fullStr | Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy |
| title_full_unstemmed | Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy |
| title_short | Potential of the Trifunctional Bispecific Antibody Surek Depends on Dendritic Cells: Rationale for a New Approach of Tumor Immunotherapy |
| title_sort | potential of the trifunctional bispecific antibody surek depends on dendritic cells rationale for a new approach of tumor immunotherapy |
| topic | Trifunctional Bispecific Antibody FACS Staining Induce Tumor Cell Killing Catumaxomab Kill Tumor Cells |
| url | https://doi.org/10.2119/molmed.2012.00140 |
| work_keys_str_mv | AT ninaeissler potentialofthetrifunctionalbispecificantibodysurekdependsondendriticcellsrationaleforanewapproachoftumorimmunotherapy AT josefmysliwietz potentialofthetrifunctionalbispecificantibodysurekdependsondendriticcellsrationaleforanewapproachoftumorimmunotherapy AT ninadeppisch potentialofthetrifunctionalbispecificantibodysurekdependsondendriticcellsrationaleforanewapproachoftumorimmunotherapy AT peterruf potentialofthetrifunctionalbispecificantibodysurekdependsondendriticcellsrationaleforanewapproachoftumorimmunotherapy AT horstlindhofer potentialofthetrifunctionalbispecificantibodysurekdependsondendriticcellsrationaleforanewapproachoftumorimmunotherapy AT ralphmocikat potentialofthetrifunctionalbispecificantibodysurekdependsondendriticcellsrationaleforanewapproachoftumorimmunotherapy |